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Molecular pathology is now an integral part of diagnostic
pathology. Thishas brought excitementandresponsibilitiesto
us as pathologists and molecular biologists in pathology—
excitement, due to the many new possibilities we have for
diagnosis, prediction of outcome, and response to therapy of
disease, and responsibilities, since we need to perform the
tests with high accuracy, which requires expertise. But is this
different from conventional histology and immunohisto-
chemistry? At the time of Virchow, histopathology
brought about enormous excitement, and as we are all
aware, the responsibilities became rapidly clear. The first
attempt to diagnose a tumor in 1882, on a biopsy of a
Crown Prince, resulted in a failure, which led to many
publications on this topic. Many of us remember the
early days of immunohistochemistry, again enormous
excitement, many publications (still ongoing) on its use,
and obviously, great responsibilities since without immuno-
histochemistry, manydiagnoses are impossibleor, atthe least,
unreliable. But the pathologists looking down the microscope
remained the final decision makers. And we all know that a
good pathologist can make a correct diagnosis on a poor
slide and/or a poor immunostained slide, but without
knowledge and experience, even the best slide does not
suffice. For molecular pathology, it is different.
For molecular tests (excluding fluorescent in situ hybridiza-
tion, which is often regarded by pathologists as a bit
fancier immunostain), the tissue is ground, DNA or RNA is
extracted and processed, and bands, or colors or letters, appear
on a screen, blot, or paper. These need to be interpreted in the
context of the histological and immunohistochemical findings
in order for a final conclusion to be drawn. This needs team-
work between a molecular biologist and pathologist, and both
need to understand each other's trade. For pathologists, it is
important to realize that there are factors that may influence the
molecular results, factors such as fixation, tissue processing,
and DNA extraction to name just a few. For molecular biolo-
gists, these issues are well known, but they also need to be
informed about the exact diagnosis and the absolute and rela-
tivequantityoftumorcellsandotherpotentialtestconfounders.
Not only that, both need to be aware of the test characteristics
specific to the questions asked. That this is crucial can be
learned from the KRAS story in colorectal cancer.
EGFR targeting agents have a modest effect on metasta-
sized colorectal cancer. As it turned out, they are only
effective on tumors with a wild-type KRAS gene, but in
patients with a KRAS mutated tumor, the drug even has a
negative effect. It is therefore mandatory that the test is
performed with high accuracy. Therefore, the European
Society of Pathology has initiated a European external
quality assurance system, which is now in its fourth year
[1–3]. Through this program, it has become clear not
only that many different test systems can provide reliable
results, but also that about 10–15% of the laboratories
committed unacceptable mistakes (the good news, however,
is that after feedback, these laboratories performed signifi-
cantly better). It has also become clear that there are
major differences in the pre-analytical phase between labo-
ratories, that there are problems when, in a sample, the
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extraction methods matter.
In this issue, Lee et al. describe a novel PCR-based
method for KRAS testing and compare the results with the
most commonly used test, Sanger sequencing [4]. This latter
method is quite robust, but may show failures in case the
sample contains a low percentage of tumor cells. The
TaqMelt PCR assay—the cobas® KRAS Mutation Test—
designed to detect 19 mutations in codons 12, 13, and 61
was shown to be superior in sampleswitha lowpercentage
of tumor cells. The paper also discusses some of the issues
which are relevant in molecular pathology of today and is
therefore a valuable contribution to the literature, both for
pathologists and for molecular biologists. It is, however,
not the only commercial test system that provides highly
accurate results in such samples. It is important that
experiences like those from Lee et al. are published.
The results of the ESP KRAS EQA system will be published
as well. In this way, a large database with knowledge on
methods of DNA extraction and test platforms will be built
up. Such data will enable pathologists and molecular
biologists to make an argued choice for test systems for any
particular question. These choices are important, since each
new method that is going to be used for molecular pathology
needsin-housevalidation,priortoitsapplication.Thisimplies
that one cannot change too often from one test to another,
even though developments in methods of molecular testing
evolve extremely fast.
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